News|Articles|September 15, 2024
Targeted Pulse Quiz: September 15
Author(s)Morgan Bayer
Fact checked by: Tony Berberabe, MPH
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Advertisement
Ready for the challenge? Let’s begin!
Question 1 of 4: What designation did IBI363 receive from the FDA?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5






































